Etoricoxib for Parkinson's disease
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests if etoricoxib, an anti-inflammatory drug, can help people with Parkinson's disease. You may join if you have a confirmed diagnosis and are not using other anti-inflammatory drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with Parkinson's disease using the standard rating scale
- You are not pregnant, planning pregnancy, or breastfeeding
- You do not have serious liver or kidney problems
- You do not use alcohol or illegal drugs heavily
- You are not allergic to etoricoxib or taking other anti-inflammatory drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding celecoxib, an anti-inflammatory drug, to standard Parkinson's treatment can help improve symptoms. If you have Parkinson's disease and are at least 18, this study might be an option for you.
This study tests a new formulation of carbidopa-levodopa (IPX-203) to see how well it works for people with Parkinson's disease. It uses a wearable device to measure movement and aims to improve “off” time, when symptoms return between doses.
This trial tests if a low dose of carbon monoxide (HBI-002) is safe and helpful for people with Parkinson's disease. It requires specific health criteria and stable Parkinson's medication.
This trial tests whether the anti-inflammatory drug dapansutrile can help people with early Parkinson's disease. You would get either dapansutrile or a placebo (a pill with no active drug) to see if it slows the disease.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
This Phase 2 study tests whether radotinib is safe and tolerable, and whether it can help people with early Parkinson’s disease. It also checks how the body absorbs and processes the drug.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.